The EPIPHARMA Group brings together breakthrough proteomimetic peptide chemistry and a state of the art diagnostic laboratory from gene expression profiling to in vivo disease models.
The EPIPHARMA Service Company supports clients and partners in their peptide based drug development programs and provide an unparalleled laboratory research environment for characterizing, testing and evaluating new potential treatment approaches.
The EPIPHARMA Drug Company develops Proteomimetic Peptide Drugs to treat major infectious diseases.
PRESIDENT AND INVESTOR
Gábor is Life Science and Biotech leader with 20+ years diverse experience in emerging and large life science, biotech and pharma.
Gábor is a seasoned executive in building effective, externally focused organizations, raising capital and developing clinical and research product pipelines from small start-up to multinational, integrated clinical stage pharma.
His key areas of expertise include advanced technology platform innovation, asset in-licensing, research and development in pain, oncology, ED, rare diseases, orphan drugs, proctology, CF, infectious diseases, business development. In his most recent endeavour, Gábor built a pharma company from its birth as a platform technology innovation to becoming a fully-fledged pharmaceutical company with 5 drugs in pivotal clinical programs and an innovative research pipeline of multi-billion dollar market potential.
He holds MSCs in Biology, Chemistry and he has an MBA.
CHIEF SCIENTIFIC OFFICER, CO-FOUNDER
József is an expert of cell biology and pharmacology. He earned his medical degree in 2008 and his Ph.D. in theoretical medicine in 2014 at the Faculty of Medicine, University of Szeged. He studied the role of pancreatic ductal epithelial cells in the pathophysiology of acute pancreatitis. During his Ph.D. studies József became an expert in primary cell isolation and culture technologies, fluorescent microscopy and animal models of inflammatory diseases. At National Institute of Health (Bethesda, MD, USA) developed advanced cell cultures, molecular biology (molecular cloning) and microscopy techniques (FRET, TIRF, electron microscopy) for the study of molecular physiology of intracellular signalling. He contributed to several publications in leading scientific journals (J Cell Biol. 2013, Nature Communications, 2014).
In 2014 he returned to Hungary and established his laboratory at the University of Szeged. He won several research grants, including the Momentum grant of the Hungarian Academy of Sciences. His laboratory is focused on the epithelial cell signalling and secretion in physiology and pathology and to the development of novel treatments by translating basic findings into patient benefit. His laboratory combines cutting edge cell culture techniques such as 3D organoid cultures with advanced omics and imaging methods. He is the co-inventor of several novel drugs.
Beáta Mándityné Huszka
Beáta earned her M.Sc. in Pharmaceutical Chemistry in 2012 from Eötvös Loránd University, Faculty of Sciences.
In 2010 she won the prestigious Nivo prize from the Hungarian Chemical Society.
Before co-founding EPIPHARMA in 2018, she held various management positions including Head of the Laboratory and Head of Development as well as becoming a proud mum of her two beautiful children.
SENIOR STRATEGIC CONSULTANT
Dr. Mándity is head of the Institute of Organic Chemistry at Semmelweis University and group leader and PI of Artificial Transporter Research Group at the Research Center for Natural Sciences of the Hungarian Academy of Sciences.
He is a world renowned expert in the synthesis and characterization of proteomimetic systems including self-organizing peptides and foldamers. He is also a leading expert in continuous-flow synthesis. He earned his PhD in 2011 in foldamer chemistry at the Faculty of Pharmacy, University of Szeged. He was a visiting postgraduate student at Bielefeld University, Germany and University of Joensuu, Finland.
In 2017, he won the prestigious Momentum grant from the Hungarian Academy of Sciences and established his own research group at the Research Center for Natural Sciences, Budapest. His research focus is on the development of proteomimetic peptide drugs.
His research interest at the Institute of Organic Chemistry at Semmelweis University is focused in break-through green chemical synthesis processes.
He is an author and inventor of numerous high impact peer reviewed publications and patents.